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Everted sacAbstract Purpose: Desvenlafaxine succinate (DSV) is a water soluble anti-depressant drug, which
is rapidly absorbed after oral administration exaggerating its side effects. The current work aimed
to prepare controllable release DSV matrix to reduce DSV side effects related to its initial burst.
Methods: Fifteen DSV matrix formulations were prepared using different polymers, polymer/drug
ratios and matrix excipients and characterized using Differential Scanning Calorimetry (DSC),
infrared (IR) spectroscopy, water uptake and in vitro DSV release. The release kinetics were calcu-
lated to determine the drug release mechanism. Ex-vivo DSV absorption via rat intestinal mucosal
cells and the calculation of the apparent permeability coefficient (Papp) were performed using
everted sac technique. Results: Maltodextrin was the best matrix excipient (F7 and F10) showing
acceptable decrease in the initial burst compared to the innovator. The addition of negatively
charged polymers sodium carboxy methyl cellulose (SCMC) or sodium alginate resulted in an inter-
action that was proved by DSC and IR findings. This interaction slowed DSV release. F10 showed
an excellent absorption of more than 80% of DSV after 4 h and the highest similarity factor with
the innovator (84.7). Conclusion: A controllable release pattern of DSV was achieved using Metho-
cel, Maltodextrin and SCMC. The obtained results could be used as a platform to control the
release of cationic water soluble drugs that suffer from side effects associated with their initial burst
after oral administration.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).od and
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2 W. Samy et al.1. Introduction
Desvenlafaxine (DSV) is the major active metabolite of the
third generation anti-depressant, venlafaxine (Pae et al.,
2009). DSV is comparable to venlafaxine in efficacy, but elicits
lesser side effects (Coleman et al., 2012). DSV was approved by
the Food and Drug Administration (FDA) in 2008 for use in
major depressive disorder (Perry and Cassagnol, 2009). It is
also used in neuropathic pain, menopause vasomotor symp-
toms and anxiety (Pae et al., 2009).
DSV, being a weak basic drug (Vo¨lgyi et al., 2010), dis-
solves easily in gastric fluids and is highly absorbed after oral
administration, which exaggerates its side effects. Indeed, this
highlights the need to prepare extended release of DSV tablets
to increase the compliance of patients suffering from depres-
sive disorder and decrease side effects compared to the imme-
diate release formulation (Franek et al., 2015; McLaughlin
et al., 2007). Being a relatively new drug (Hussar and
Campoli, 2008), few trails have been made to develop sus-
tained release preparation of DSV. For instance, in 2015, Pay-
ghan and co-workers prepared DSV controlled release matrix
tablet by melt granulation technique using chemically inert
lipids such as Compritol 888 ATO, Precirol ATO 5 and hydro-
genated castor oil.
Combinations of hydroxypropyl methylcellulose (HPMC)
and sodium carboxymethyl cellulose (SCMC) have been uti-
lized to minimize the release of water-soluble drugs during
the initial phase of their release (Yang et al., 2013). These com-
binations tend to flatten the shape of the release profile and
produce a zero order release (Sirisolla and Ramanamurthy,
2015; Varshosaz et al., 2006). In 1997, Timmins and co-
workers optimized the ratio of anionic and non-ionic polymers
to obtain a pH-independent in vitro release of the model drug
verapamil hydrochloride. Another study has reported the
retarding effect of anionic polymers like SCMC on the release
of propranolol hydrochloride from matrix tablets (Takka
et al., 2011). Other studies investigated the swelling behavior
of matrix systems containing mixtures of HPMC and SCMC
and a model soluble drug to find the correlation between the
morphological behavior and the drug release performance
(Conti et al., 2007).
The objective of this paper was to present formulations of
controlled release properties based on tablet matrix systems
for DSV utilizing hydrophilic polymers. The everted gut sac
of the rat small intestine was used as reliable and reproducible
ex-vivo method to determine kinetic parameters of drug release
(Lipinski et al., 2001) to predict DSV absorption through
intestinal mucosal cells and calculate the apparent permeabil-
ity coefficient (Papp) of DSV formulations and compare it to
the innovator.
2. Materials & methods
2.1. Materials
Desvenlafaxine succinate monohydrate, was obtained as a gift
from Alembic Pharmaceuticals Limited, India; sodium car-
boxy methyl cellulose (CISME, Italy); maltodextrin M100
(Glucidex, Roquette Pharma, France); microcrystalline cel-
lulose ph101 (Avicel, GMW, India); magnesium stearate
(UNDESA, Spain); silicon dioxide (Aerosil200, OCI CompanyPlease cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.005Ltd., South Korea); Methocel k15M (Dow Chemical Com-
pany, USA); ethanol lactose, sodium alginate (SA) and other
chemicals (El-Nasr for chemical industries, Egypt). All chemi-
cals were of analytical grades.
2.2. Methods
2.2.1. Preparation of DSV matrix systems
Fifteen formulations (Table 1) were prepared using wet granu-
lation technique. The calculated amount of DSV was ground
in a mortar for 5 min, and then geometrically mixed with the
chosen excipient (Maltodextrin, Avicel or lactose). Finally,
the specified quantity of the main matrix polymer, Methocel
k15M, was added at a ratio of either 1:1 or 1:1.25 (drug: poly-
mer) and mixed for 10 min. For formulations containing
SCMC or SA, the selected negatively charged polymer was
added before the main matrix polymer and mixed well for
5 min.
Wet massing of mixtures was done with the required quan-
tity of ethyl alcohol 95% and the wet mass was passed through
a 0.5 mm sieve using wet granulator (Erweka FGS wet granu-
lator, Germany). The produced granules were then dried at
50 C till reaching moisture content less than 2% measured
by infrared moisture balance (Kitt, Japan). The dried granules
were finally passed through 0.5 mm sieve. Magnesium stearate
and Aerosil200 were added to the prepared granules, mixed for
5 min and stored till compression. Tablets were compressed
using single punch tablet press (TDP6 Single punch press,
China) with shallow concave punch (10 mm diameter). Tablet
weight was adjusted to 350 ± 5 mg and hardness of about
10 ± 2.0 KP using Vanguard hardness tester from USA.
2.2.2. Characterization of the prepared matrix granules
2.2.2.1. Physical characterization. The flow properties of the
prepared granules were measured using flowability tester
(BEP2 Copley Flowability Tester, UK) to determine the angle
of repose. The bulk volume of granules was obtained by pour-
ing an amount of 1 g the granules in 10 ml graduated cylinder.
Volume was recorded and the bulk density was calculated.
Tapped density was measured using tapped density tester
(JV1000 Copley Tapped Density Tester, UK). Carr’s Com-
pressibility Index, an indication of the compressibility of a
powder, was determined according to the following equation:
Carr’s Index ð%Þ ¼ 100 ðTapped Density
 Bulk densityÞ=Tapped density ð1Þ
where the tapped density is the increased bulk density resulting
from mechanically tapping the container containing the pow-
der sample.
2.2.2.2. Differential scanning calorimetry (DSC). The use of
negatively charged polymers (SCMC or SA) can lead to inter-
actions with the tested cationic drug (DSV). In order to inves-
tigate such interactions, thermograms of DSV, SCMC, SA and
their physical mixtures were recorded using differential scan-
ning calorimeter (DSC 6, Perkin Elmer, USA) to test the phys-
ical state of DSV inside the matrix of prepared tablets.
DSV-polymer mixtures were prepared either by wet granu-
lation or by co-precipitation method in the same ratio utilized
in the prepared formulations. In co-precipitation method,
DSV was dissolved in 100 ml water with the negatively chargedral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Table 1 Composition of different DSV matrix systems.a
Formula code Methocel k15M SCMC SA Maltodextrin M100 Avicel ph101 Lactose monohydrate
F1 76 – – 193 – –
F2 76 – – – 193 –
F3 76 – – – – 193
F4 95 – – 174 – –
F5 95 – – – 174 –
F6 95 – – – – 174
F7 76 76 – 117 – –
F8 76 76 – – 117 –
F9 76 76 – – – 117
F10 95 76 – 98 – –
F11 95 76 – – 98 –
F12 95 76 – – – 98
F13 95 – 7.6 166.4 – –
F14 95 – 15.2 158.8 – –
F15 95 – 22.8 151.2 – –
a An amount of 76 mg DSV was incorporated in each formula. A quantity of 1.5 mg Aerosol 200 and 3.5 magnesium stearate were added to
each formulation to obtain a final tablet weight of 350 mg.
Hybrid polymeric matrices modify Desvenlafaxine release 3polymer, poured into small glass dish and left to dry at 50 C.
The produced solid mixture was scrapped and thermally ana-
lyzed. Samples were weighed and placed into aluminum pans,
which were then sealed, held at 35 C for 1 min under a flow of
nitrogen, and then heated to 350 C at a rate of 10 C/min.2.2.2.3. Fourier transform infrared (FTIR) spectroscopy. IR
spectra were recorded using FT-IR spectrometer (IRAffinity-
1S, Shimadzu FT-IR spectrophotometer, Japan) for DSV,
SCMC, SA and their physical mixtures. Samples were finely
ground with KBr (infrared grade), and pressed into pellets
and the IR spectra were taken in transmission over the range
of 4000–500 cm1.2.2.3. Characterization of the compressed matrix tablets
2.2.3.1. Drug content. Ten tablets were finely powdered and a
sample of 350 mg (equivalent to 76 mg of DSV) was accurately
weighed and transferred to 500 ml volumetric flask containing
250 ml of 0.9% w/v sodium chloride. The content was stirred
with intermittent sonication (Branson 3510 Ultra sonic, Mex-
ico) for 1 h to ensure complete extraction of DSV. The volume
was completed with 0.9% w/v sodium chloride and filtered
through 0.45 lm millipore filter and DSV content was ana-
lyzed spectrophotometrically (Shimadzu UV 1800 spectropho-
tometer, Japan) at the predetermined kmax of 231 nm of the
first derivative spectrum. At this wavelength none of the excip-
ients interfered with the calibration curve. A good linearity was
obtained from 0.844 to 8.44 mg % DSV concentration with a
determination coefficient (R2) of 0.99983. The amount of DSV
dissolved in the medium was determined by the following
equation:Content of DSV ¼ ðAtest=AstandardÞ  100 ð2Þwhere A, is the absorbance of the dissolved DSV for both test
and standard.Please cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.0052.2.3.2. Tablet hardness and friability. The vertically mounted
tablet was squeezed using Vanguard hardness tester and the
breaking load was determined in KP.
Friability testing according to USP-XXXII, a sample of
tablets corresponding to 6.5 g was taken. The tablets were
carefully de-dusted prior and after testing. Tablet sample was
accurately weighed and placed in the drum of Vanguard fri-
ability tester, USA. The drum was rotated 100 times, tablets
were accurately weighed and the percent friability was calcu-
lated by the following equation:
%Friability ¼ ½ðw1  w2Þ=w1  100 ð3Þ2.2.3.3. In-vitro tablet dissolution and kinetic analysis of release
data. Tablet dissolution requirements adopted by FDA (FDA,
2015) were applied to the prepared formulations. Dissolution
study for the prepared formulations and the innovator con-
taining 76 mg DSV was carried out using USP-XXXII dissolu-
tion apparatus I (Hanson research SR8 plus dissolution testing
apparatus, USA) in 900 ml 0.9% w/w sodium chloride solution
maintained at 37 ± 0.5 C at basket speed of 100 rpm. At the
designated time intervals, 10 ml of the release medium was
withdrawn and replaced with the same volume of pre-heated
release medium. All samples were run in triplicate and filtered
through 0.45 lm membrane filters and the amount of DSV
released was analyzed by measuring absorbance of the first
derivative UV spectrum at predetermined kmax.
Similarity factor (SF) was utilized to describe dissolution
rate for each formulation compared with the innovator. This
factor is a logarithmic reciprocal square root transformation
of the sum of squared error and is a measurement of the sim-
ilarity in percent dissolution between the two curves. It was
calculated using the following equation (Shah et al., 1998):
SF ¼ 50 log 1þ ð1=nÞ
Xn
t¼1
ðRt TtÞ2
" #0:5
 100
8<
:
9=
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4 W. Samy et al.where ‘‘n” is the number of time points, ‘‘Rt” is the percentage
release value of the reference batch at time t and ‘‘Tt” is the
percentage release value of the test batch at time t.
For evaluation of release kinetics, the obtained release data
for formulations that passed similarity factor testing were fit-
ted into first order, zero order and Higuchi equations. Selec-
tion of the best model was based on the comparisons of the
relevant coefficients of determination. The release data were
subjected to kinetic analysis using Korsmeyer–Peppas model
correlating drug release to time by simple exponential equation
for the fraction of drug release <0.6.
F ¼Mt=M1 ¼ k tn ð5Þ
where ‘‘Mt/M1” is the proportion of drug released at time t,
‘‘k” is the kinetic constant and the release exponent ‘‘n” has
been proposed as indicative of the drug release mechanism.
2.2.3.4. Swelling behavior and surface wetting of the matrix
tablets. The formulation showing maximum similarity with the
innovator, F10, was selected along with those containing the
same drug/polymer ratio and negatively charged polymer to
perform swelling test in 0.9% w/v sodium chloride solution.
The weighed tablets were immersed in 900 ml of the medium
for 10 h and at selected time intervals the swollen tablets were
collected on filter paper, the wet tablet weight was determined
using analytical balance. The percentage swelling of tablets
was calculated from the equation:
Percentage Swelling ¼ ½ðWtW0Þ=W0  100 ð6Þ
where ‘‘Wt” denotes the weight of swollen tablet at time ‘‘t”
and ‘‘W0” is the initial weight of tablets. Each experiment
was repeated three times and the average value was taken.
A morphological study on swelling and erosion of the
selected formulations was conducted using digital camera.
Photographs of tablets freshly removed from the dissolution
medium in an hourly basis, were taken with the same magnifi-
cation and distance from the camera.
An indication of the degree of water penetration to the
tabletcore was estimated by dropping one drop of 1% w/v bril-
liant blue in water on the tablet surface using an insulin syr-
inge. Diameter of the colored spot on the tablet surface after
1 min gives indication about degree of surface wetting of the
tablets, and hence water penetration.2.3. Ex-vivo study using everted sacs
2.3.1. Development of HPLC method for determination of DSV
The method is based on separation of DSV using C8 column
(4.6  150 mm) 5 lm. A mixture of phosphate buffer (5 mM,
pH 3.8): acetonitrile (50%:50%) was used as mobile phase.
The mobile phase was filtered through 0.45 lm Millipore filter
and degassed before being pumped at flow rate 0.6 ml/min.
The injection volume was 20 lL and the peaks were detected
at 229 nm by UV detector with a total run time of 6 min. A cal-
ibration curve (peak area versus drug concentration) was con-
structed by running the working standard solutions of DSV for
every series of chromatographed samples.
Stock standard solution was prepared by dissolving DSV in
the mobile phase to a final concentration of 35.2 lg/ml. Lin-
earity was confirmed by preparing serial dilutions of DSV overPlease cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.005the range 4.4–17.6 lg/ml. The method was validated according
to USP-XXXII validation elements and the ICH guidelines.
Specificity, accuracy and ruggedness of the method were also
confirmed.
2.3.2. Preparation of everted sacs
Adult female Wistar rats weighing 150–160 g were used. All
experiments were performed in strict accordance with Institu-
tional Animal Care and Use Guidelines. After an overnight
fast, rats were humanely sacrificed under thiopental anesthesia
(Helmy and El-Gowelli, 2012; Samy et al., 2012) and the small
intestine was quickly excised and flushed with sodium chloride
solution (0.9% w/v) at room temperature. The removed
intestines were immediately placed in warm (37 C), freshly
prepared oxygenated Ringer Locke solution. The jejunum
was cut into 8–10 cm segments and gently everted over a glass
rod (2.5 mm diameter). One end of each segment was closed
using surgical silk thread (non-absorbable suture, 3–0,
0.2 mm diameter), filled with fresh oxygenated Ringer-Locke
solution and sealed with a second silk thread. For each exper-
iment, 16 sacs were prepared. Segments from different rats
were randomly assigned to different dissolution cups to mini-
mize biological variation (Alam et al., 2012).
2.3.3. Ex-vivo dissolution study
An ex-vivo dissolution study for the prepared formulation F10
matrix tablet and the innovator, each containing 76 mg DSV,
was carried out using USP-XXVIII dissolution apparatus II
using the pH-change method. The first step was done by plac-
ing the tested formulation in 750 ml simulated gastric fluid
without enzymes (pH 1.2) maintained at 37 ± 0.5 C at paddle
speed 60 rpm for 2 h. At designated time intervals, a volume of
10 ml of the release medium was withdrawn and replaced with
the same volume of preheated release medium. All samples
were filtered through 0.45 lm membrane filter and the amount
of DSV released was analyzed by HPLC. The second step
started after 2 h of gastric conditions and lasted for 4 h in
Ringer Locke solution (USP-XXXII), pH (7.2–7.4) with a
source of oxygen bubbles in the medium.
Three everted intestinal sacs each filled with 1 ml Ringer
Locke solution and firmly tied from both ends by a silk thread
were hanged to the paddle of the dissolution apparatus in each
dissolution jar. At 1 h intervals, 10 ml of the release medium
was withdrawn and replaced with the same volume of pre-
warmed Ringer Locke solution. Every hour, the everted sacs
taken from one cup were individually emptied into clean test
tube and the volume was measured. DSV either transferred
into the serosal fluid or entrapped inside the mucosal cells of
the everted sac was determined using HPLC.
2.3.4. Sample preparation of DSV transferred to serosal fluid
The intestinal sacs at specified time intervals were emptied and
an equal volume of acetonitrile was added to the obtained ser-
osal fluid and the sample was centrifuged at 4000 rpm for
30 min to ensure complete precipitation of proteins and cell
debris. A volume of 1 ml from the supernatant was diluted
to 10 ml with purified water in volumetric flask. The amount
of DSV transferred to serosal fluid was measured using the
developed HPLC method and expressed as mean concentra-
tion of DSV in each sac ± SD.ral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Hybrid polymeric matrices modify Desvenlafaxine release 52.3.5. Sample preparation of DSV entrapped in the mucosal cells
The emptied sacs were washed with 0.9% w/v saline and kept
at 4 C till measurement. Mucosal cells of the intestinal sacs
were scrapped using glass slide, weighed and a specified vol-
ume of 0.9% w/v saline was added to prepare 40% homoge-
nate. The prepared homogenate was subjected to cycles of
freezing and thawing at room temperature with vortexing in
order to facilitate mucosal cell rupture and release the
entrapped DSV. The volume of the homogenate was accu-
rately measured and an equal volume of acetonitrile was added
and the mean DSV concentration in each sac ± SD was deter-
mined as previously mentioned.2.3.5.1. Determination of the relative DSV amount transferred.
The comparison of DSV transferred to serosal compartment
relative to donor compartment for prepared formulations
was done using the following equation:
Relative DSV transferred ð%Þ
¼ DSV ðlg=mlÞ in the receiving compartment ðserosal fluidÞ
DSV ðlg=mlÞ in the donor compartment ðbulk fluidÞ
 100
ð7Þ2.3.5.2. Comparison of the apparent permeability of the tested
matrix. The apparent permeability (Papp) was calculated
according to the equation (Le Ferrec et al., 2001):
Papp ¼ dQ=dt 1=AðC0Þ ð8Þ
where ‘‘dQ/dT” is the cumulative amount of drug (Q) appear-
ing in the serosal compartment as a function of time obtained
from the slope of the linear portion of the amount transported-
versus-time plot, and ‘‘A” is the calculated surface area of the
intestinal sac (cm2). ‘‘C0” is the initial concentration of drug in
the donor compartment (lg/ml). Since the concentration in the
donor compartment was variable due to presence of sustained
release dosage form, Papp was calculated for each interval
separately.Table 2 Physical properties of the prepared matrix granule formul
Formula code qo (g ml
1) qt (g ml
1) Hau
F1 0.32 ± 0.12 0.42 ± 0.12 1.31
F2 0.32 ± 0.10 0.41 ± 0.10 1.27
F3 0.40 ± 0.15 0.51 ± 0.15 1.27
F4 0.39 ± 0.14 0.52 ± 0.14 1.32
F5 0.39 ± 0.15 0.53 ± 0.15 1.33
F6 0.39 ± 0.11 0.51 ± 0.11 1.27
F7 0.42 ± 0.12 0.51 ± 0.12 1.21
F8 0.41 ± 0.12 0.50 ± 0.12 1.22
F9 0.42 ± 0.08 0.50 ± 0.08 1.22
F10 0.41 ± 0.08 0.49 ± 0.08 1.20
F11 0.39 ± 0.11 0.47 ± 0.11 1.19
F12 0.44 ± 0.12 0.53 ± 0.12 1.22
F13 0.39 ± 0.12 0.49 ± 0.12 1.25
F14 0.37 ± 0.13 0.47 ± 0.13 1.25
F15 0.36 ± 0.09 0.45 ± 0.09 1.25
qo: bulk (pour) density, qt: tapped density.
Please cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.0052.3.6. Statistics
Values were expressed as mean ± SD. The data were statisti-
cally analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Newman–Keuls multiple comparison test with an
equal sample size. The difference was considered significant
when P values < 0.05 using Graph pad prism, version 3.02.
3. Results and discussion
3.1. Characterization of matrix granules
3.1.1. Physical characterization
The prepared matrix formulations were characterized for dif-
ferent physicochemical properties (Table 2). The angle of
repose of the prepared formulations varied from 22 to 28
showing excellent flow. For the same excipient, increasing
DSV:Methocel ratio from 1:1 to 1:1.25 had no remarkable
effect on the physical properties of the prepared formulations
(Carr’s index, Hausner ratio or angle of repose). Addition of
the negatively charged polymers SCMC or SA in formulations
F7 to F15 slightly improved the flow properties of the prepared
granules as denoted in Carr’s index and Hausner ratio values.
3.1.2. Estimation of possible drug-polymer interactions
DSC studies of powdered DSV indicated a shallow melting
endothermic peak at 113.3 C and another broad peak at
236.7 C (Fig. 1). For DSV-SCMC granulated mixture, the
first endothermic peak was shifted to 127.8 C, while the other
peak was formed at 242.9 C. DSV-SCMC co-precipitate
showed absence of the first endothermic peak of the drug
and a sharp endothermic peak is formed at about 223.4 C.
This may indicate possible interaction between DSV and
SCMC, which occurred during tablet exposure to the aqueous
medium (Fig. 1D).
For DSV-SA granulated mixture, the first endothermic
peak was shifted to 105.9 C, while the other peak was formed
as a broad peak in the range 200–250 C. For DSV-SA co-
precipitate, there was no shift in the endothermic peak at
113.2 C, but only a change in the peak area. It was also shownations.
sner’s ratio Carr’s index Angle of repose (h)
23.51 (pass) 25.64 ± 0.20 (Excellent)
21.37 (pass) 28.44 ± 0.18 (Excellent)
21.21 (pass) 22.93 ± 0.23 (Excellent)
24.32 (pass) 22.62 ± 0.17 (Excellent)
24.71 (pass) 23.75 ± 0.22 (Excellent)
21.30 (pass) 25.56 ± 0.17 (Excellent)
17.54 (Fair) 22.90 ± 0.19 (Excellent)
17.80 (Fair) 26.56 ± 0.19 (Excellent)
18.20 (Fair) 24.62 ± 0.21 (Excellent)
16.46 (Fair) 25.64 ± 0.22 (Excellent)
16.00 (Fair) 22.61 ± 0.21(Excellent)
18.11 (Fair) 26.56 ± 0.17 (Excellent)
20.40 (Fair) 27.55 ± 0.18 (Excellent)
20.12 (Fair) 24.44 ± 0.18 (Excellent)
20.00 (Fair) 23.49 ± 0.20 (Excellent)
ral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Figure 1 Thermal analysis of (A) DSV, (B) CMC, (C) DSV-CMC granulated mixture, (D) DSV-CMC co-precipitate.
6 W. Samy et al.that the endothermic peak of DSV at 236.7 C became very
minute or almost disappeared (Fig. 2).
3.1.3. Infrared spectroscopy
FT-IR spectra of SCMC, DSV, DSV-SCMC granulated and
co-precipitated mixtures are shown in Fig. 3. DSV shows char-
acteristic absorption bands at 3166.77 cm1 corresponding to
OAH groups. Another characteristic band at 1654.33 cm1
characterizes C‚O group of carboxylate anion found in the
succinate salt (Fig. 3A). Alternatively, SCMC typically shows
characteristic absorption bands at 3100–3550 cm1 relative
to OAH groups. Other absorption bands at 1155.34,
1269.89, 1325.99 and 1420.99 cm1 were attributable to the
CAOAC groups. Another characteristic band at 1604–1690Please cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.005cm1 is attributable to C‚O group (Fig. 3B). DSV-SCMC
granulated mixture almost shows no change in the absorption
bands of DSV and SCMC mentioned above (Fig. 3C),
whereas, the DSV-SCMC co-precipitate shows complete
masking of the absorption bands, which characterizes DSV
and SCMC (Fig. 3D).
In case of SA, typical characteristic absorption bands were
seen at 3094–3415 cm1 relative to the OH groups. Absorption
bands at 1176.1 cm1 and 1426.38 cm1 are attributable to
CAOAC groups. Another characteristic band was attributed
to C‚O group at 1645.01 cm1 (Fig. 4B). DSV-SA granulated
mixture shows slight shift of OAH group to 3182.43 cm1,
while the characteristic band of C‚O group appears at
1647.8 cm1. DSV-SA co-precipitate shows a shift of C‚Oral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Figure 2 Thermal analysis of (A) DSV, (B) SA, (C) DSV-SA granulated mixture, (D) DSV-SA co-precipitate.
Hybrid polymeric matrices modify Desvenlafaxine release 7group to 1625.49 cm1 together with band broadening of
OAH group that appeared at 3436.94 cm1 indicating a possi-
ble drug polymer interaction.
3.2. Characterization of prepared tablets
The prepared formulations were successfully transformed into
tablets. This good compressibility of the prepared formula-
tions may be attributed to the presence of inter-particular
voids as evidenced by the calculated Carr’s index.
3.2.1. Drug content
All prepared formulations showed good homogeneity of DSV
within the compressed tablets, where the drug content of the
prepared formulations was within the range of 100 ± 5%.Please cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.0053.2.2. Hardness and friability of the compressed tablets
Hardness of the compressed tablets was adjusted at the range
of 10 ± 2 Kp. This was assured by measuring tablet hardness
for each compressed formulation. Friability of the compressed
tablets was less than 1%.
3.2.3. In-vitro drug release
According to the FDA (2015), 0.9%w/v sodium chloride was
considered the most suitable dissolution medium for DSV.
Fig. 5a shows the percentage cumulative DSV release of for-
mulations F1-F3 compared to the innovator. It was clear that
the innovator release was slower than the formulations con-
taining DVS:Methocel ratio of 1:1. To obtain a slower release,
the ratio of Methocel was increased to be 1:1.25 (F4-F6). The
higher concentrations of Methocel resulted in slower releaseral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Figure 3 Infrared charts of (A) DSV, (B) SCMC, (C) DSV-
CMC granulated mixture and (D) DSV-CMC co-precipitate.
Figure 4 Infrared charts of (A) DSV, (B) SA, (C) DSV-SA
granulated mixture and (D) DSV-SA co-precipitate.
8 W. Samy et al.(Fig. 5b) that was still slightly higher than the innovator.
Alternatively, formulations containing lactose (F4 and F6)
showed the highest release, which can be attributed to the
water solubility of lactose. The slowest release of DSV was
from matrices containing maltodextrin (F1, F4) possibly due
to the small aqueous pores found in case of maltodextrin
due to gel formation upon contact with water, which can form
coherent diffusion barrier that delays further percolation of the
hydration medium (Chronakis, 1998; Levina and Rajabi-
Siahboomi, 2004; Mason et al., 2015). It has been reported that
modified starches (maltodextrins) could be used efficiently in
the reduction of drug release rate from controlled release
tablets because of their cold water-swelling capacity forming
gel barrier (Bravo et al., 2002; Nickerson et al., 2006).
Another trial to modulate DSV release was made by incor-
porating the negatively charged polymer SCMC while keeping
the 1:1 drug:polymer ratio (F7-F9). It was shown from Fig. 5c
that F7 release was close to that of the innovator, while F8 and
F9 (containing Avicel or lactose, respectively) were faster than
the innovator.
Upon combining the effect of the high polymer ratio (Drug:
Methocel ratio of 1:1.25) and the addition of negativelyPlease cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.005charged polymers SCMC (F10-F12) or SA (F13-F15) the
release pattern of DSV could be greatly modulated with the
disappearance of the initial burst of DSV in the first hour of
release (Fig. 5d and e). The slowest release profile was obtained
when both Methocel and SCMC or SA were used in the for-
mulation, where 100% of the drug dissolution occurred after
24 h. This indicated potential synergistic interaction (chemical
and/or physical) between drug–polymer and/or polymer–poly-
mer. This was supported by the obtained thermograms of
DSV, SCMC, SA, and mixtures of DSV with these negatively
charged polymers. Notably, in other studies where SCMC for-
mulations with hydrophilic polymers (HPMC) and propra-
nolol HCl were investigated, it was suggested that
dissolution was mainly controlled by an interaction between
the cationic drug and the anionic polymer (Nickerson et al.,
2001).
According to the semi-mechanistic model conducted by
Franek et al. (2015), our results of a more delayed drug release
are more preferable compared to faster release preparations.
This is mainly due to the suggestion that Desvenlafaxine
absorption from Immediate Release Formulation (IRF) is
rate-limited by permeability, whereas Desvenlafaxine absorp-
tion from Extended Release Formulations (ERFs) is likelyral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Figure 5 In-vitro DSV release pattern from different matrix tablets.
Hybrid polymeric matrices modify Desvenlafaxine release 9rate-limited by dissolution due to the formulation. Conse-
quently, the prepared formulations can provide a better mod-
ulation of drug release that may eliminate any release-related
side effects by simple changes in the used matrix.
3.2.4. Estimation of similarity factor values comparing with
innovator product
The value of Similarity Factor (SF) is a good parameter for
comparison of release data as it takes into consideration all
release points rather than a single one. The results of dissolu-Please cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.005tion studies were expressed in terms of similarity factor values
comparing with innovator results at different time intervals.
Similarity factor values greater than 50 ensure equivalence of
the two curves (Shah et al., 1998), the tested formula and the
innovator product.
For the same type of matrix excipient, formulations con-
taining higher concentration of Methocel had greater similar-
ity factor than those containing lower concentration.
Generally, for the same drug, polymer ratio, the tested matrix
excipients can be ranked according to their similarity of DSVral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Figure 6 Percentage swelling of different DSV matrix tablet
formulations (F10, F11 and F12) compared with the innovator in
0.9% w/v sodium chloride at 37 C (Table 1).
10 W. Samy et al.release pattern compared with the innovator as follows: mal-
todextrin (F1, F4, F7 and F10) > Avicel (F2, F5, F8 and
F11) > lactose (F3, F6, F9 and F12). This rank is supported
by the calculated values of similarity factor.
Of the tested formulations only four formulations had SF
higher than 50, namely F7, F8, F10 and F11 with SF of
76.4, 53.6, 84.7 and 66.6, respectively. Another ranking of sim-
ilarity can be done to compare the effect of incorporation of
negatively charged polymers (Table 3). Of all the tested formu-
lations, F10 showed the highest similarity factor (SF = 84.68)
at DVS:Methocel ratio of 1:1.25, which was selected to be of
optimum compositions.
3.2.5. Calculation of release kinetics
In order to investigate the mode of release of DSV from the
prepared controlled-release formulations, the release data were
analyzed with various mathematical models. The (r2) of vari-
ous models was calculated for the formulations containing
maltodextrin and high SF with the innovator (F7, F10, F14
and F15). They were ranked in the following order : Kors-
meyer > Higuchi > first order > zero order > Hixson-
Crowell.
Since the release exponent was found to be
0.45 < n< 0.89, release of DSV is done mainly by Kors-
meyer–Peppas mechanism from these formulations. This
means that the drug transport mechanism is an anomalous
transport drug release by a non-Fickian diffusion in which
both drug diffusion and polymer erosion contribute to drug
release.
3.2.6. Swelling behavior of the compressed tablets
A comparative swelling study (Fig. 6) was performed for the
innovator against F10, F11 and F12 containing different
matrix excipients (maltodextrin, Avicel and lactose, respec-
tively), high polymer content (drug:polymer ratio of 1:1.25)
and one negatively charged polymer (SCMC). The F10 for-
mula containing maltodextrin as a matrix excipient showed
swelling behavior that was very close to that of the innovator
product followed by F11 containing Avicel. The percentage
swelling in case of F10 and F11 was higher than that of the
innovator, where it increased gradually by time but in a faster
rate in case of F11. Conversely, addition of lactose as matrix
excipient in F12 showed a very rapid swelling, which reached
a maximum after 4 h followed by gradual decrease possibly
due to the high water solubility of lactose.
When hydrophilic matrix tablets are placed in 0.9% w/v
sodium chloride solution, the solution starts to penetrate theTable 3 Effect of negatively charged polymers and matrix excipien
formulations compared with the innovator.
DSV:Methocel ratio Matrix excipient Formulation rank Cor
1:1 Maltodextrin F7 > F1 76.3
1:1 Avicel ph 101 F8 > F2 53.6
1:1 Lactose F9 > F3 39.2
1:1.25 Maltodextrin F10 > F4 84.6
1:1.25 Avicel ph 101 F11 > F5 66.5
1:1.25 Lactose F12 > F6 40.6
1:1.25 Maltodextrin F14 > F4 60,1
1:1.25 Maltodextrin F15 > F4 53.7
Please cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.005matrix creating a dynamic process involving polymer wetting,
polymer hydration, gel formation, swelling and polymer disso-
lution. The polymer quickly hydrates on the outer tablet skin
to form gelatinous layer. A rapid formation of this gelatinous
layer is critical to prevent wetting of the interior and disinte-
gration of the tablet core. Once the original protective gel layer
was formed, it controls the penetration of additional water
into the tablet (Mason et al., 2015).
During the process of polymer hydration, soluble excipients
or drugs are also wetted, dissolved and start diffusion out of
the matrix, while insoluble materials are held in place until
the surrounding polymer/excipient/drug complex is eroded or
dissolved away. This is why the mechanisms by which drug
released from matrix tablets are dependent on the rate and
extent of each of these stages.
Modified starch (maltodextrin) is characterized by rapid
formation of the outer gelatinous layer due to its swelling
behavior, which prevents rapid penetration of dissolution med-
ium inside the tablet core barrier (Bravo et al., 2002; Nickerson
et al., 2006). This can explain the slow swelling of the other
matrix excipients utilized in formulations F11 and F12.
The three tablet formulations F10, F11 and F12 were exam-
ined just after being removed from the soaking medium on an
hourly basis. Lactose, a water-soluble excipient with hydrophi-
lic nature, creates high osmotic pressure inside the swelledts on similarity factor of DSV dissolution profiles from different
responding similarity factor Negatively charged polymer utilized
57 > 46.518 SCMC
20 > 42.387 SCMC
56 > 33.725 SCMC
80 > 48.539 SCMC
38 > 42.261 SCMC
71 > 37.646 SCMC
40 > 48.539 SA
64 > 48.539 SA
ral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
Figure 7 Surface wetting and penetration of brilliant blue
solution to the prepared matrix tablets containing different matrix
excipients.
Table 4 Ex-vivo DSV permeation into different compartments and the calculated donor compartment, mucosal cells and serosal fluid
concentrations at different time intervals.
Time (h) Release medium pH Formula DSV concentration dQ/dT lg/min Papp  105 cm/s
Donor lg/mL Mucosal cells lg/g Serosal fluid lg/mL
1 (pH 1.2) Innov. 18.76 ± 0.63
F10 20.64 ± 0.76
2 (pH 1.2) Innov. 25.30 ± 0.53
F10 21.20 ± 0.50
3 (pH 7.4) Innov. 36.10 ± 0.30 33.26 ± 0.014 18.37 ± 7.44 0.306 2.5
F10 35.20 ± 0.45 119.83 ± 0.022 16.96 ± 3.70 0.282 2.4
4 (pH 7.4) Innov. 44.75 ± 0.54 102.38 ± 0.041 40.95 ± 3.07 0.376 1.9
F10 44. 0 ± 0.60 134.21 ± 0.021 34.10 ± 6.01 0.285 1.0
5 (pH 7.4) Innov. 49.80 ± 0.95 132.76 ± 0.011 48.30 ± 5.00 0.122 0.50
F10 49.00 ± 0.90 176.83 ± 0.011 47.01 ± 1.73 0.215 0.85
6 (pH 7.4) Innov. 54.80 ± 0.65 223.55 ± 0.050 50.08 ± 4.40 0.029 0.12
F10 53.60 ± 0.62 196.75 ± 0.196 50.19 ± 2.73 0.053 0.19
Figure 8 Percentage cumulative DSV absorbed from mucosa
and passed to the serosal compartment relative to donor
compartment of F10 and the innovator.
Hybrid polymeric matrices modify Desvenlafaxine release 11matrix forming more micro-cavities in polymer matrices, facil-
itating gel formation and shortening the penetration time of
the dissolution medium into the matrix. Moreover, this soluble
substance acts as a channeling agent by rapidly dissolving and
easily diffusing outward, therefore decreasing tortuosity and/
or increasing the matrix porosity (Sangalli et al., 2001). This
explains the higher swelling and erosion of matrix polymer
in case of utilizing lactose as matrix excipients than Avicel
and maltodextrin.
The ability of tablets to absorb water is another factor that
can affect drug release. This was examined by visual estimation
of the diameter of a colored spot formed on tablet surface after
one minute upon adding one drop of brilliant blue solution on
the tablet surface using an insulin syringe. Tablets containing
maltodextrin as matrix excipient showed the slowest penetra-
tion rate followed by Avicel then lactose; this was observed
from the diameter of the formed colored spot (Fig. 7).
3.3. Ex-vivo dissolution study
The amount of DSV released in simulated gastric fluid (pH
1.2) in the donor compartment from F10 (matrix tablet) wasPlease cite this article in press as: Samy, W. et al., Hybrid polymeric matrices for o
Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.005almost the same as the innovator (Table 4). DSV released after
pH change to 7.4 was also determined in the bulk solution out-
side the sacs for the two formulations.
DSV release from the matrix tablet and the innovator pro-
duct in case of pH gradient method was the same as that
obtained by the method adopted by FDA using 0.9% w/v
sodium chloride as dissolution medium. Thus, it can be con-
cluded that the release of DSV from the matrix tablets either
the innovator or F10 was pH-independent. After 6 h about
54 lg/ml of DSV was released from either F10 or innovator.
Since the concentration in the donor compartment was vari-
able with continuous drug release from the dosage form, dQ/
dT (the change in serosal concentration) was calculated from
the slope for each interval separately.
Within an in vitro system, Papp is useful parameter to com-
pare the permeability of different drug molecules (Le Ferrec
et al., 2001). The average Papp of DSV released from the pre-
pared formula was 1.234  105 cm/s. This is closelyral modified release of Desvenlafaxine succinate tablets. Saudi Pharmaceutical
12 W. Samy et al.approaching the value of Papp for mannitol (1.7  105 cm/s)
that represents a good permeability marker for hydrophilic
compounds (Brown et al., 2002; Vora et al., 2015). Similarity
factor of Papp of the prepared formulation calculated at differ-
ent time intervals was very high (99.9987) indicating a close
similarity between apparent permeability of DSV released
from the tested formulation and that of the innovator.
After 4 h the amount transferred relative to the donor com-
partment exceeded 80% for the tested formulation F10 (Fig. 8)
and there was no significant difference between the prepared
formulation and the innovator at the end of simulated intesti-
nal fluid period. This indicated good absorption of DSV from
the prepared formulations into the intestinal sacs.
4. Conclusion
The formulation of DSV in a hybrid matrix using the hydro-
philic polymer Methocel, maltodextrin excipient and the nega-
tively charged polymer SCMC seems to be a successful and
simple technique to modulate drug release and prevent the ini-
tial burst. The prepared granules were successfully compressed
into tablets having a pH-independent release and excellent
intestinal absorption. The obtained results could be used as a
platform for modulating the release of similar hydrophilic
drugs whose side effects are related to the release pattern.
Appendix A. Supplementary material
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jsps.2016.
10.005.
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